Results 161 to 170 of about 692,269 (276)

Self‐Assembly of Therapeutic Peptides for Enhanced Cancer Therapy: Strategies, Therapeutic Performance, and Future Perspectives

MedComm – Biomaterials and Applications, Volume 5, Issue 4, December 2026.
Therapeutic peptide self‐assembly is governed by multiple non‐covalent interactions, enabling the construction of diverse supramolecular structures. These self‐assembled systems can be engineered through spontaneous self‐assembly of monomers, co‐assembly, or stimulus‐responsive strategies to improve tumor delivery efficiency.
Yuelin Fang, Xue Wan, Shihe Wang, Honglan Dai, Huiling Zeng, Nan Chen, Xinxin Zhang   +6 more
wiley   +1 more source

Proto‐Panic Modulation by Caffeine‐Proteinoid Complexes

Journal of Applied Polymer Science, Volume 143, Issue 41, November 5, 2026.
Caffeine–proteinoid microspheres synthesized by thermal polymerization exhibit compartmentalized drug loading with encapsulation efficiencies of 61%–82% and triphasic release kinetics. Electrochemical monitoring reveals multi‐scale oscillatory dynamics consistent with chaotic and damped harmonic behavior, while Boolean logic operations demonstrate ...
Panagiotis Mougkogiannis, Andrew Adamatzky   +1 more
wiley   +1 more source

MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future. [PDF]

Pharmacol Rev
Wang W, Albadari N, Du Y, Fowler JF, Sang HT, Xian W, McKeon F, Li W, Zhou J, Zhang R.   +9 more
europepmc   +1 more source

Covalent drug discovery: Progress against key targets, emerging strategies and lessons learnt

British Journal of Pharmacology, Volume 183, Issue 22, Page 6574-6606, November 2026.
Abstract Covalent drug discovery is currently experiencing a boom in industrial and academic interest. To date, at least 75 covalent drugs have received regulatory approval, targeting both traditional target classes and more challenging proteins for which other approaches failed. In many cases, unique aspects of covalent targeting are essential for the
Charles P. Brown, Alan Armstrong, David J. Mann   +2 more
wiley   +1 more source

Histone deacetylase inhibitors as venetoclax‐sensitising partners in acute myeloid leukaemia: Mechanisms, pharmacology and translational perspectives

British Journal of Pharmacology, Volume 183, Issue 21, Page 6261-6290, November 2026.
Abstract Venetoclax combined with hypomethylating agents has improved treatment for older or unfit patients with acute myeloid leukaemia (AML), but resistance and relapse remain common. This review analyses the rationale for combining venetoclax with inhibitors of histone deacetylase (HDAC).
Jaebok Lee, Marc Diederich
wiley   +1 more source

MDM2 inhibitors induce apoptosis by suppressing MDM2 and enhancing p53, Bax, Puma and Noxa expression levels in imatinib‑resistant chronic myeloid leukemia cells. [PDF]

Biomed Rep
Kimura A, Tsubaki M, Obana T, Matsuo T, Komori R, Nagai N, Yamamoto T, Nishida S.   +7 more
europepmc   +1 more source

Hybrid Macrocyclic Peptides — Synthetic Strategies to Diversify and Cyclize Peptide Libraries in Phage Display Selections

Chemistry – A European Journal, Volume 32, Issue 39, 22 October 2026.
Hybrid macrocyclic peptides unite genetically encoded peptide libraries with the structural complexity of synthetic small molecules. This Review critically analyzes phage‐compatible cyclization and diversification chemistries, highlights emerging opportunities beyond traditional cysteine‐based approaches, and outlines how future advances may enable the
Titia Rixt Oppewal, Clemens Mayer
wiley   +1 more source

Small molecule NMD and MDM2 inhibitors synergistically trigger apoptosis in HeLa cells. [PDF]

Mol Cells
Li Y, Wan L, Li H, Tang X, Xu S, Sun G, Huang W, Tang M.   +7 more
europepmc   +1 more source

New Insights into Chemoresistance Mediated by Mdm2 Inhibitors: The Benefits of Targeted Therapy over Common Cytostatics. [PDF]

Biomedicines
Grigoreva T, Sagaidak A, Novikova D, Tribulovich V.   +3 more
europepmc   +1 more source

MDM2 Inhibitor KRT-232 [PDF]

, 2020
openaire   +1 more source